January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Latest Content from Inizio
An overview of the five most-commonly researched, largest pharma markets in North Asia.
Pegasus, the UK’s leading independent health communications consultancy, picked up the ‘Excellence in Patient/Consumer Health Programmes’ award at last week’s prestigious Communiqué Awards 2015 with its ‘Faces of HAE’ campaign...
Pegasus shortlisted for three Communiqué awards and hopes to defend its Communications Consultancy of the Year win from 2014
An overview of the PsO biologic and systemic patientOur PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot...
An overview of the prostate cancer patientDownload our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by...
Latin AmericaThe LATAM regions largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With...
An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...
The Central and Eastern Europe region is home to over 145 million people and is a key global growth region. With pharmaceutical sales set to exceed $27bn in 2014, it...
Home to over half a billion people, the ASEAN region constitutes the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an...
Referencing data from our Living with HCV survey undertaken with patients in the US and China, this infographic explores the roadblocks encountered on the path to effective and compliant treatment.Hepatitis C is...
